The Zika virus poses a significant threat to regions across the Pacific, Southeast Asia, India, Africa, South, and Central America. While it typically causes mild illness, infection during pregnancy can result in miscarriages, stillbirths, or infants born with congenital malformations. The lack of a licensed vaccine has left many vulnerable.
In response to the Zika outbreak, researchers at The University of Adelaide developed a unique vaccine that targets a specific protein, NS1, within the virus. This approach ensures that vaccination does not exacerbate symptoms for individuals infected with related viruses, such as dengue fever.